|
|
|
|
|
|
|
|
|
|
|
24.09.26 - 13:01
|
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product (GlobeNewswire EN)
|
|
|
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the United States Food and Drug Administration (FDA) to implement a new potency assay, T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of all new commercial product lots of its FDA-approved mesenchymal stromal cell (MSC) product Ryoncil® (remestemcel-L-rknd)....
|
|
|
|
|
24.09.26 - 02:48
|
Mesoblast wins FDA nod for new Ryoncil potency test (Fool)
|
|
|
Mesoblast gets FDA approval for a new Ryoncil potency assay, aiming to ensure quality and support product expansion.
The post Mesoblast wins FDA nod for new Ryoncil potency test appeared first on The Motley Fool Australia....
|
|
|
01.09.26 - 06:36
|
Buy, hold, sell: Challenger, APA Group, Mesoblast shares (Fool)
|
|
|
Experts reveal their insights on these stocks in the finance, utilities, and healthcare sectors.
The post Buy, hold, sell: Challenger, APA Group, Mesoblast shares appeared first on The Motley Fool Australia....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
